Biotechnology

JACOBIO-B

Jack Bio-Continues Share Buyback and Announces Ample Cash Reserves

J 科思-B repurchased 66,000 shares for HKD 472,800

J 科思-B repurchased 68,400 shares for about HKD 494,400

JACOBIOTECH-B Repurchased Shares for HKD 249,700

JACOBIOTECH-B Receives USD 100 Million Milestone Payment from AstraZeneca

J 科思-B Announces 2025 Results and Receives $100 Million Prepayment from AstraZeneca

JACOBIO-B released FY2025 9 Months Earnings on March 10, 2026 (BJT) with actual revenue of HKD 53.74 M and EPS of HKD -0.1438

JACOBIO-B released FY2025 Q3 earnings on March 10, 2026 (BJT), actual revenue HKD 4.297 M, actual EPS HKD -0.0613

JACOBIO-B released FY2025 earnings on March 10 After-Market (BJT), actual revenue HKD 58.5 M (forecast HKD 127 M), actual EPS HKD -0.206

JACOBIO-B released FY2025 Q4 earnings on March 10 After-Market (BJT), actual revenue HKD 4.371 M, actual EPS HKD -0.0634

JACOBIO-B to Release FY2025 Annual Earnings on March 10 After-Market (BJT), Forecast Revenue HKD 128.52 M

J 科思-B repurchased 240,000 shares for HKD 1,484,600

J 科思-B repurchases 150,000 shares

AstraZeneca and JABYO Enter into a License Agreement, Jacada Shares Under Pressure

AstraZeneca's Involvement in Jiakang KRAS Inhibitor Project Shifts Pharmaceutical Industry Competition Landscape

JAKSION BIOSCIENCE SUBSIDIARY RECEIVES FIRST PAYMENT FROM HISON CAPITAL

J 科思-B publishes KRAS G12C inhibitor combination therapy clinical trial results

JACOBIOTECH-B repurchased 72,000 shares for HKD 498,300

JAKSON BIOSCIENCE REPUCHASED 72,000 SHARES FOR HKD 482,300

J 科思-B repurchased 66,000 shares for HK$463,000

HINSANG GROUP

RIVERINE CHINA

PASHUN INT RTS

BRAINAURORA-B

SOFTMEDX

GOLDENPOWER

ZHONGKE GROUP

VISION SYNERGY

GEMILANG INTL

GHPC

01167

Jacobio Pharmaceuticals has repurchased 747,800 shares for HK$34.17 million, citing undervaluation of its oncology pipeline. The company has enhanced liquidity with a US$100 million payment from AstraZeneca and RMB8.55 million in royalties, totaling approximately RMB2.1 billion in cash and credit. This financial strength supports ongoing oncology development and global expansion. Analysts rate the stock as a Buy with a target price of HK$10.34.

Tip Ranks

AstraZeneca PLC

AstraZeneca

Allist

Jacobio Boosts Share Buybacks and Liquidity as Oncology Pipeline Advances

159849

513700

159506

159316

588130

159892

516500

562050

159570

JACOBIO Pharmaceutical Group Co., Ltd. is expected to turn a profit by 2026, mainly due to its collaboration with AstraZeneca and the market promotion of its KRAS G12C inhibitor, Aerie. The company will enter its first year of commercialization in 2025, with Aerie successfully included in the national medical insurance catalog, and sales revenue from profit-sharing is expected to increase significantly. In addition, early clinical data for the pan-KRAS inhibitor JAB-23E73 has shown excellent performance, demonstrating good safety and efficacy

BambooWorks

China Merchants CSI Biotechnology Theme ETF

Health Care Select Sector SPDR

Yinhua CSI Innovative Drugs Industry ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

E Fund CSI Biotechnology Theme ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

iShares US Pharma

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

Penghua CSI HK Connect Health Care Composite ETF

VanEck Biotech ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

SPDR S&P Biotech

E Fund Hang Seng SCHK Innovative Drug ETF

ChinaAMC SSE STAR Biology and Medicine ETF

iShares Global Healthcare

Bosera Hang Seng Health Care ETF(QDII)

Bosera Hang Seng SCHK Innovative Drug Select ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

VG Health

First Trust NYSE Arca Biotech Index Fd

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

E Fund CSI 300 Health Care ETF

ChinaAMC CSI Biotechnology Theme ETF

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

Guotai CSI Bio-medicine ETF

Minsheng Royal CSI Biotechnology Theme ETF

Hwabao WP CSI Pharmaceuticals ETF

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

China Universal CNI HK Connect Innovative Drugs Industry ETF

JACOBIO enters its first year of commercialization, with strong BD support, and profitability expected by 2026

Huachuang Securities analyst maintained a Buy rating on Jacobio Pharmaceuticals Group Co., Ltd. yesterday and set a price target of HK$11.65.Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Jacobio Pharmaceuticals Group Co., Ltd. with a HK$11.00 average price target.

Huachuang Securities Sticks to Its Buy Rating for Jacobio Pharmaceuticals Group Co., Ltd. (1167)

Jacobio Pharma, a leading biopharmaceutical company, revealed its financial performance for the year ending December 31, 2025. The company's commercial product Glecirasib was officially approved and included in China's NRDL. Additionally, Jacobio Pharma continues to progress its pan-KRAS and Innovative ADC Pipeline. The company made this announcement on March 10, 2026, with headquarters in Beijing, Shanghai, and Boston. Jacobio Pharma is listed on the Hong Kong Stock Exchange under the ticker symbol 1167. This signifies a significant advancement for the company as it consolidates its presence in the pharmaceutical industry.

Unusual Whales

Jacobio Announces 2025 Annual Results

02477

06886

09678

00565

06681

03928

01024

01873

00622

WELLCELL HOLD(02477) fell 10.19%, with a trading turnover 49.2 Million HKD, and a year-to-date fell 27%. HTSC(06886) fell 8.24%, with a trading turnover 1.6 Billion HKD, and a year-to-date fell 10%. UNISOUND(09678) fell 6.48%, with a trading turnover 330.3 Million HKD, and a year-to-date fell 12.9%.

Top Gainers&Losers

WELLCELL HOLD

HTSC

UNISOUND

ART GROUP HOLD

CHINA NEXT-GEN

KUAISHOU-W

VIVA BIOTECH

OSHIDORI

Top 10 HK Stock Losers (2.3)

JACOBIO-B (1167.HK) consolidated with reduced volume yesterday, with the stock price operating within a limited range, repeatedly testing the resistance at HKD 8.08 without success. The biopharmaceutical sector is still in a high valuation correction phase, and overall market risk appetite has declined. The company has had no significant new drug development or financing movements in the past two weeks, leading to a cautious stance among main investors, focusing on range trading and active arbitrage. Although acquisition news in the sector has attracted attention, the effect has not transmitted to JACOBIO. The technical chart shows a continuation of the MACD death cross, with short-term moving averages trending downward and selling pressure persisting. If there is a rebound, trapped positions at high levels may actively seek to break even, making the market prone to repeated washout characteristics. In the short term, if there are clinical news on new drugs or industry mergers, it may ignite sentiment; otherwise, right-side capital operations need to remain cautious, and risk exposure must be strictly controlled. Aggressive accumulation is not recommended without strong signals

Technical Forecast

Morning Trend | JACOBIO-B reduces volume and grinds at the bottom, will an upward opportunity emerge?

01045

02595

00842

02865

03696

03939

02575

01122

06960

APT SATELLITE(01045) rose 20.85%, with a trading turnover 158.9 Million HKD, and a year-to-date rose 54.3%. GENFLEET-B(02595) rose 15.67%, with a trading turnover 60.8 Million HKD, and a year-to-date rose 15.5%. LEOCH INT'L(00842) rose 14.22%, with a trading turnover 72.6 Million HKD, and a year-to-date rose 30.4%.

APT SATELLITE

GENFLEET-B

LEOCH INT'L

DRINDA

INSILICO

WANGUO GOLD GP

XUANZHUBIO-B

QINGLING MOTORS

SHUANGDENG

Top 10 HK Stock Gainers (1.8)

02418

02718

06166

06082

08603

06600

01729

DEEWIN(02418) fell 22.71%, with a trading turnover 22.3 Million HKD, and a year-to-date fell 24%. MININGLAMP-W(02718) fell 8.49%, with a trading turnover 48.5 Million HKD, and a year-to-date fell 1.5%. JACOBIO-B(01167) fell 7.23%, with a trading turnover 43.5 Million HKD, and a year-to-date fell 3.3%.

DEEWIN

MININGLAMP-W

BIREN TECH

FAMEGLOW

ONEROBOTICS

TIME INTERCON

Top 10 HK Stock Losers (1.6)

02282

02635

01952

01969

02145

00931

02592

02617

02068

MGM CHINA(02282) fell 17.14%, with a trading turnover 631.2 Million HKD, and a year-to-date rose 37.7%. NUOBIKAN(02635) fell 15.11%, with a trading turnover 23.4 Million HKD, and a year-to-date rose 320%. EVEREST MED(01952) fell 14.97%, with a trading turnover 729.9 Million HKD, and a year-to-date fell 21.6%.

JACOBIO-B(01167.HK)